The offering, which is expected to close around July 16, 2026, includes 6,027,399 shares of common stock and 4,931,506 pre-funded warrants. Underwriters have also been granted a 30-day option to purchase an additional 1,643,835 shares. Morgan Stanley, Jefferies, and Cantor Fitzgerald are leading the book-running process for the capital raise.
Q32 Bio Prices $200 Million Stock Offering for Autoimmune Research
Waltham-based Q32 Bio has priced a $200 million public offering of common stock and pre-funded warrants, aiming to bolster its clinical pipeline. The biotechnology firm is selling over 6 million common shares at $18.25 each, with proceeds earmarked to accelerate the development of its lead candidate, bempikibart.
Q32 Bio plans to deploy the net proceeds toward general working capital and the advancement of bempikibart, an anti-IL-7Rα antibody currently in Phase 2 trials for alopecia areata. This autoimmune condition affects roughly 700,000 people in the United States, representing a significant area of focus for the company’s clinical strategy. The securities were issued under a shelf registration statement declared effective by the SEC on July 13.
Comments (0)
No comments yet. Be the first!